SecurityKPTI / Karyopharm Therapeutics Inc.
IndustryPharmaceutical Preparations
Institutional Buyers63
Opened Positions17

Institutional and Fund Ownership - Buyers

Major holders that have opened new positions in KPTI / Karyopharm Therapeutics Inc. include Delphi Ventures Viii Lp, venBio Select Advisor LLC, Private Capital Advisors, Inc., Doheny Asset Management /ca, Millennium Management Llc, Citadel Advisors Llc, Kennedy Capital Management, Inc., Ghost Tree Capital, LLC, Schonfeld Strategic Advisors LLC, Millennium Management Llc, Citadel Advisors Llc, Citadel Advisors Llc, Springbok Capital Management, Llc, Pnc Financial Services Group, Inc., Daiwa Securities Group Inc., Federated Investors Inc /pa/, and Valeo Financial Advisors, Llc.

This page shows changes in the ownership structure by listing institutions, funds, and major shareholders that have increased their holdings or opened new positions in the last reporting period. Green rows indicate new positions. Click the link icon to see the full transaction history.

File DateFormInvestor Option Prev Shares Shares Change
(Percent)
Prev Value
(x$1000)
Current Value (x$1000) Change
(Percent)
2018‑05‑15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 280,610 321,323 14.51 2,693 4,312 60.12
2018‑05‑14 13F-HR/A CITADEL ADVISORS LLC Put 0 17,000 0 228
2018‑05‑15 13F-HR PANAGORA ASSET MANAGEMENT INC 146,918 150,022 2.11 1,410 2,013 42.77
2018‑04‑26 13F-HR SIMPLEX TRADING, LLC Call 34 88 158.82 6 37 516.67
2018‑05‑04 13F-HR Swiss National Bank 56,850 64,150 12.84 546 861 57.69
2018‑05‑02 13F-HR RHUMBLINE ADVISERS 32,585 33,560 2.99 313 450 43.77
2018‑05‑15 13F-HR GOLDMAN SACHS GROUP INC 78,107 111,545 42.81 750 1,497 99.60
2017‑08‑11 13F-HR FT Options LLC Call 41,900 126,200 201.19 130 69 -46.92
2018‑05‑15 13F-HR D. E. Shaw & Co., Inc. 72,771 175,541 141.22 699 2,356 237.05
2018‑05‑15 13F-HR Schonfeld Strategic Advisors LLC 250,000 362,892 45.16 2,400 4,870 102.92
2018‑05‑11 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 500 7
2018‑05‑14 13F-HR VIRTUS ETF ADVISERS LLC 36,973 81,325 119.96 355 1,091 207.32
2018‑05‑15 13F-HR BARCLAYS PLC 28,526 42,985 50.69 273 577 111.36
2018‑05‑02 13F-HR Daiwa Securities Group Inc. 261 4
2018‑05‑15 13F-HR VANGUARD GROUP INC 1,801,391 1,936,043 7.47 17,293 25,981 50.24
2018‑05‑10 13F-HR TCW GROUP INC 40,648 43,448 6.89 390 583 49.49
2018‑05‑14 13F-HR Itau Unibanco Holding S.A. 962 3,490 262.79 9 47 422.22
2018‑05‑14 13F-HR Virtu Financial LLC 0 24,710 0 332
2018‑05‑03 13F-HR MEEDER ASSET MANAGEMENT INC 0 80 0 1
2018‑07‑13 13F-HR BANK OF MONTREAL /CAN/ 0 344 0 6
2017‑02‑14 SC 13D/A DELPHI VENTURES VIII LP 2,303,006
2018‑05‑15 13F-HR SPRINGBOK CAPITAL MANAGEMENT, LLC Call 2,000 27
2018‑05‑15 13F-HR Bank of New York Mellon Corp 163,093 167,107 2.46 1,566 2,243 43.23
2018‑05‑14 13F-HR/A CITADEL ADVISORS LLC Call 0 14,300 0 192
2018‑04‑26 13F-HR SIMPLEX TRADING, LLC Put 8 22 175.00 0 6
2018‑05‑15 13F-HR venBio Select Advisor LLC 560,658 7,524
2018‑05‑09 13F-HR BlackRock Inc. 2,639,151 2,758,063 4.51 25,335 37,014 46.10
2017‑02‑10 13F-HR BlackRock Institutional Trust Company, N.A. 539,090 556,383 3.21 5,245 5,230 -0.29
2018‑05‑14 13F-HR/A CITADEL ADVISORS LLC 54,308 93,940 72.98 521 1,261 142.03
2018‑04‑12 13F-HR Valeo Financial Advisors, Llc 7 0
2018‑05‑16 13F-HR/A GROUP ONE TRADING, L.P. 0 8,246 0 111
2017‑02‑10 13F-HR BlackRock Group LTD 6,616 6,994 5.71 64 66 3.13
2018‑05‑11 13F-HR BNP PARIBAS ARBITRAGE, SA 7,123 7,897 10.87 68,381 105,978 54.98
2018‑05‑15 13F-HR Wellington Management Group LLP 6,042,653 6,808,383 12.67 58,010 91,369 57.51
2018‑05‑15 13F-HR BANK OF AMERICA CORP /DE/ 42,559 44,892 5.48 408 602 47.55
2017‑02‑10 13F-HR BlackRock Investment Management, LLC 101,972 103,508 1.51 992 973 -1.92
2018‑05‑09 13F-HR NORTHERN TRUST CORP 385,717 397,294 3.00 3,702 5,331 44.00
2018‑05‑11 13F-HR CITIGROUP INC 3,541 21,330 502.37 34 286 741.18
2018‑05‑04 13F-HR STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM 14,761 15,549 5.34 142 209 47.18
2018‑05‑15 13F-HR CREDIT SUISSE AG/ 40,053 46,089 15.07 384 619 61.20
2018‑02‑09 13F-HR RidgeWorth Capital Management LLC 0 36,973 0 355
2018‑05‑15 13F-HR UBS Group AG 2,278 19,632 761.81 21 264 1,157.14
2018‑05‑11 13F-HR CITADEL ADVISORS LLC 93,940 1,261
2018‑05‑15 13F-HR MILLENNIUM MANAGEMENT LLC Call 41,100 552
2018‑05‑14 13F-HR TIAA CREF INVESTMENT MANAGEMENT LLC 79,898 262,388 228.40 767 3,521 359.06
2018‑04‑26 13F-HR SIMPLEX TRADING, LLC 6,646 21,808 228.14 63 292 363.49
2018‑05‑15 13F-HR TWO SIGMA INVESTMENTS LLC 24,220 121,888 403.25 233 1,636 602.15
2018‑05‑11 13F-HR CITADEL ADVISORS LLC Put 17,000 228
2018‑05‑16 13F-HR/A GROUP ONE TRADING, L.P. Put 0 500 0 7
2018‑05‑07 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 150,289 168,188 11.91 1,443 2,258 56.48
2018‑05‑15 13F-HR MILLENNIUM MANAGEMENT LLC 436,836 1,272,268 191.25 4,194 17,074 307.11
2017‑02‑10 13F-HR BlackRock Advisors LLC 11,410 13,558 18.83 111 127 14.41
2018‑05‑14 13F-HR UNITED SERVICES AUTOMOBILE ASSOCIATION 81,670 86,376 5.76 784 1,159 47.83
2018‑05‑16 13F-HR DOHENY ASSET MANAGEMENT /CA 228,990 3,073
2018‑05‑10 13F-HR NEW YORK STATE COMMON RETIREMENT FUND 30,500 37,700 23.61 293 506 72.70
2018‑05‑09 13F-HR FEDERATED INVESTORS INC /PA/ 215 3
2018‑05‑15 13F-HR Ghost Tree Capital, LLC 76,786 1,030
2018‑05‑14 13F-HR MORGAN STANLEY 69,928 147,612 111.09 671 1,981 195.23
2018‑05‑15 13F-HR Palo Alto Investors, LLC 3,544,439 3,679,978 3.82 34,027 49,385 45.13
2018‑05‑15 13F-HR CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 53,278 54,111 1.56 511 726 42.07
2018‑05‑15 13F-HR MILLENNIUM MANAGEMENT LLC Put 150,000 2,013
2018‑05‑11 13F-HR CITADEL ADVISORS LLC Call 14,300 192
2018‑05‑15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Put 25,200 33,200 31.75 242 446 84.30
2018‑05‑14 13F-HR KENNEDY CAPITAL MANAGEMENT, INC. 92,720 1,244
2018‑05‑02 13F-HR WELLS FARGO & COMPANY/MN 30,974 36,036 16.34 298 483 62.08
2018‑05‑03 13F-HR Trexquant Investment LP 0 31,017 0 416
2018‑05‑03 13F-HR DekaBank Deutsche Girozentrale 0 20,300 0 269
2018‑05‑04 13F-HR PRUDENTIAL FINANCIAL INC 19,130 68,736 259.31 184 923 401.63
2017‑02‑10 13F-HR BlackRock Fund Advisors 1,147,261 1,376,355 19.97 11,163 12,938 15.90
2018‑05‑15 13F-HR STATE STREET CORP 589,786 988,931 67.68 5,663 13,272 134.36
2018‑05‑15 13F-HR METROPOLITAN LIFE INSURANCE CO/NY 11,177 11,719 4.85 107 157,269 146,880.37
2018‑05‑15 13F-HR Cubist Systematic Strategies, LLC 963 25,385 2,536.03 9 341 3,688.89
2018‑05‑15 13F-HR Schonfeld Strategic Advisors LLC Call 50,000 30
2018‑05‑15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 80,300 120,700 50.31 771 1,620 110.12
2018‑07‑10 13F-HR Private Capital Advisors, Inc. 416,900 7,083

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

43m - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

22h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 48576U106